By Callum Keown and Al RootSpaceX stock has a problem — it's failing to get off the ground despite several catalysts.The shares might get a boost on Monday as it starts trading having joined a major stock index, the Russell 1000 after the Friday close. That qualifies as a minor catalyst. The amount…
(12:13 GMT) Quantinuum Price Target Announced at $98.00/Share by Evercore ISI Group
Roche Holding's new gene-sequencing platform gives it a chance to take Illumina's crown in the market, Bernstein analysts say in a research note. The market for next-generation sequencing is expected to grow at an annual rate of 11% over the next decade to reach about $15.5 billion in 2035, and Roc…
By Bowdeya TwehA lot of funds tracking the Nasdaq 100 may soon be holding SpaceX shares.Nasdaq confirmed plans to accelerate the timeline for the Elon Musk-led company to be included in its widely followed index. SpaceX will be included prior to the market open on July 7.After crossing into $200-a…
(12:11 GMT) Alkermes Price Target Announced at $38.00/Share by B of A Securities
(12:09 GMT) Liquidia Price Target Raised to $79.00/Share From $64.00 by B of A Securities
(12:09 GMT) Liftoff Mobile Price Target Announced at $42.00/Share by Needham
XR, Eni: LNG is Liquified Natural Gas
(12:07 GMT) Solaris Energy Infra Price Target Announced at $97.00/Share by Needham
By Robb M. StewartAegis Brands President and Chief Executive Steven Pelton will relinquish the company's reins before his successor is picked, leaving an executive committee to lead day-to-day operations.The owner of the St. Louis Bar & Grill brand and holder of the master franchise for the Sweet J…
XRG, Eni: Blocks Part of Integrated 12M Tons/Year Argentina LNG Project
Replimune FY Loss/Shr $3.38 >REPL
Replimune 4Q Loss $73.7M >REPL
(12:04 GMT) Amphastar Pharmaceuticals Price Target Cut to $20.00/Share From $25.00 by B of A Securities
XRG, Eni: YPF to Retain 36% in Blocks
Replimune: FDA Considers This Complete, Class 1 Response With Goal Date of Aug 2 >REPL
XRG, Eni to Buy 32% Interest in 3 Upstream Vaca Muerta Blocks from YPF
Replimune Believes Existing Cash, Cash Equivalents and Short-Term Investments Will Fund Ops Into 1Q 2027
Replimune: FDA Notified the Co to Expect Advisory Committee Meeting in Late July >REPL
Replimune : FDA Accepted for Review BLA Resubmission for RP1 (Vusolimogene Oderparepvec) in Combo With Nivolumab for Advanced Melanoma>REPL
